PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23686226-0 2013 A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma. Cyclophosphamide 78-94 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 23-29 2471557-1 1989 Pretreatment of mice with recombinant murine (rM) colony-stimulating factor-granulocyte-macrophage (CSF-gm) or recombinant human (rH) CSF-g provides partial protection from the lethal effects of ionizing radiation or the alkylating agent cyclophosphamide (CTX). Cyclophosphamide 238-254 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 50-106 2656523-7 1989 In GM-CSF-treated mice, the neutrophil levels in peripheral blood started to increase 5 days after CPA administration and were consistently higher than those in controls. Cyclophosphamide 99-102 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 3-9 2476892-7 1989 When each of the cytokines was administered subcutaneously four times daily into cyclophosphamide-treated mice before intravenous infection with HSV, only GM-CSF revealed any protective activity. Cyclophosphamide 81-97 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 155-161 35576032-0 2022 Ameliorative effect of flavocoxid on cyclophosphamide-induced cardio and neurotoxicity via targeting the GM-CSF/NF-kappaB signaling pathway. Cyclophosphamide 37-53 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 105-111 3135686-3 1988 In addition, this CSF induced faster recoveries of neutrophils in the peripheral blood and progenitor spleen cells of cyclophosphamide (CY)-treated mice. Cyclophosphamide 118-134 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 18-21 3135686-3 1988 In addition, this CSF induced faster recoveries of neutrophils in the peripheral blood and progenitor spleen cells of cyclophosphamide (CY)-treated mice. Cyclophosphamide 136-138 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 18-21 3107475-8 1987 rhG-CSF was demonstrated to accelerate the recovery from neutropenia induced in mice and monkeys by 5-fluorouracil or cyclophosphamide. Cyclophosphamide 118-134 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 4-7 32172395-0 2020 Characterization of a Long-Acting Site-Specific PEGylated Murine GM-CSF Analog and Analysis of Its Hematopoietic Properties in Normal and Cyclophosphamide-Treated Neutropenic Rats. Cyclophosphamide 138-154 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 65-71 11532345-1 2001 OBJECTIVE: Primitive hematopoietic stem cell function was assessed after cyclophosphamide with granulocyte-macrophage colony-stimulating factor (GM-CSF), with or without preadministration of interleukin-1, using competitive repopulation. Cyclophosphamide 73-89 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 145-151 21908736-4 2011 Administration of CY mediated a significant delay in the post-IL-12/GM-CSF T suppressor cell rebound, resulting in a 7-fold increase in the CD8(+) CTL/T suppressor cell ratio, a 3-fold enhancement of CTL cytotoxicity, and an extension of the effector window from 3 to 7 d. In long-term therapy studies, chronic chemoimmunotherapy promoted a dramatic enhancement of tumor regression, resulting in complete cure in 44% of the mice receiving CY plus IL-12/GM-CSF. Cyclophosphamide 18-20 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 68-74 21908736-4 2011 Administration of CY mediated a significant delay in the post-IL-12/GM-CSF T suppressor cell rebound, resulting in a 7-fold increase in the CD8(+) CTL/T suppressor cell ratio, a 3-fold enhancement of CTL cytotoxicity, and an extension of the effector window from 3 to 7 d. In long-term therapy studies, chronic chemoimmunotherapy promoted a dramatic enhancement of tumor regression, resulting in complete cure in 44% of the mice receiving CY plus IL-12/GM-CSF. Cyclophosphamide 18-20 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 453-459 20501834-4 2010 In this model, GM-CSF reversed cyclophosphamide-induced leukopenia but also promoted breast cancer and prostate cancer growth in the bone but not in soft tissue sites. Cyclophosphamide 31-47 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 15-21 20047504-4 2010 The study by Wada and colleagues employed an autochthonous prostate cancer mouse model to demonstrate that low-dose cyclophosphamide given prior to a cell-based GM-CSF-secreting vaccine (T-GVAX) abrogated immune tolerance, augmented prostatic CD8(+) T-cell infiltration, mediated depletion of regulatory T cells (Tregs), and increased expression of dendritic cell maturation markers. Cyclophosphamide 116-132 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 161-167 16985290-5 2006 GM-CSF production in the splenocytes from the CY-treated mice was higher than that in normal mice regardless of SCG stimulation. Cyclophosphamide 46-48 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 0-6 16985290-7 2006 The level of cytokine induction by SCG was regulated by the amount of endogenous GM-CSF produced in response to CY treatment in a dose-dependent manner. Cyclophosphamide 112-114 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 81-87 9536121-4 1998 In naive mice, irradiated and cyclophosphamide-treated mice, GM-CSF did not affect the course of L. monocytogenes infection in thigh muscle, spleen and liver. Cyclophosphamide 30-46 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 61-67 11325840-0 2001 Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cyclophosphamide 0-16 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 87-135 11325840-6 2001 We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine"s potential to delay tumor growth in neu transgenic mice. Cyclophosphamide 14-30 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 101-107 7957569-6 1994 DC propagated from the blood of cyclophosphamide-treated mice in granulocyte/macrophage-colony stimulating factor-supplemented media also expressed E-cadherin. Cyclophosphamide 32-48 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 65-113 7640348-2 1995 This effect was induced rapidly (within 1 h) and persisted for 4 h. Mice made leukopenic with cyclophosphamide retained the ability to respond to GM-CSF. Cyclophosphamide 94-110 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 146-152 7897201-4 1995 Mice with the anti-GM-CSF activity reconstituted their peripheral white blood cells with identical kinetics as control mice after high dose cyclophosphamide treatment, sublethal irradiation, or lethal irradiation followed by syngeneic bone marrow transplantation. Cyclophosphamide 140-156 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 19-25 1995731-2 1991 In mice myelosuppressed by cyclophosphamide, subcutaneously administered rmGM-CSF was a potent stimulus of granulopoiesis by increasing the number of GM-CSF-responsive precursor cells in bone marrow followed by a profound neutrophilia. Cyclophosphamide 27-43 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 75-81 8157285-4 1994 T cells from CY/OVA treated mice and cells from mice injected subcutaneously with OVA in CFA responded well to both OVA and the H2d restricted peptide epitope pOVA323-339 releasing GM-CSF. Cyclophosphamide 13-15 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 181-187 1329443-3 1992 Both MDP-Lys(L18) and GM-CSF were effective for the protection against HSV infection in cyclophosphamide (CY)-treated mice. Cyclophosphamide 88-104 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 22-28 1329443-3 1992 Both MDP-Lys(L18) and GM-CSF were effective for the protection against HSV infection in cyclophosphamide (CY)-treated mice. Cyclophosphamide 106-108 colony stimulating factor 2 (granulocyte-macrophage) Mus musculus 22-28